Phenotypic variation of an ALK‐positive large‐cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors
Authors:
- 9 September 2017
- journal article
- letter
- Published by Wiley in Histopathology
- Vol. 72 (4) , 707-710
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain MetastasesThe Oncologist, 2017
- High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid MorphologyAmerican Journal of Surgical Pathology, 2017
- A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the PancreasAmerican Journal of Surgical Pathology, 2016
- Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like SubsetsClinical Cancer Research, 2016
- Transformation to SCLC after Treatment with the ALK Inhibitor AlectinibJournal of Thoracic Oncology, 2016
- Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinomaLung Cancer, 2016
- Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK InhibitorInternal Medicine, 2016
- A Case of Atypical Carcinoid: Harboring Variant 3a/b EML4–ALK RearrangementJournal of Thoracic Oncology, 2015
- A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor CrizotinibJournal of Thoracic Oncology, 2014